FY2025 · ended Dec 31, 2025 · Revenue $1.01B, +7.9% YoY · Filed Feb 19, 2026
Tandem Diabetes Care, Inc. (TNDM) files with the SEC under industry code 3841, Surgical & Medical Instruments & Apparatus. In fiscal 2025, which ended Dec 31, 2025, it reported revenue of $1.0 billion and a net loss of $204.7 million. Free cash flow was -$29.7 million. As of Jun 30, 2026 it held $456.0 million in cash and investments and $739.3 million in total debt.
Revenue (TTM)
$1.04B
+4.0% vs year-ago TTM
Net income (TTM)
$-63.31M
+69.2% vs year-ago TTM
Operating cash flow (TTM)
$-5.52M
-156.8% vs year-ago TTM
Free cash flow (TTM)
$-26.62M
-243.1% vs year-ago TTM
EPS (TTM)
$-0.93
+70.1% vs year-ago TTM
Dividend per share
None
Shares outstanding
68.33M
+2.8% vs prior year
Net cash
$-283.26M
as of Jun 30, 2026
Operating margin
-4.4%
FY 2026
Company profile
- Industry
- Surgical & Medical Instruments & Apparatus (SIC 3841)
- Listed as
- TNDM (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- San Diego, CA
- SEC filer status
- Large accelerated filer
- SEC CIK
- 1438133
Other Surgical & Medical Instruments & Apparatus companies
- Stryker Corp SYK
- 3M Co MMM
- Boston Scientific Corp BSX
- Becton Dickinson & Co BDX
- Medline Inc. MDLN
- Resmed Inc RMD
- Dexcom Inc DXCM
- Fresenius SE & Co. KGaA FSNUY
All 151 Surgical & Medical Instruments & Apparatus companies
Key figures
Fiscal-year totals from the annual reports. Balance sheet lines are as of each year end.
| Line | FY 2025 Dec 31, 2025 |
FY 2024 Dec 31, 2024 |
FY 2023 Dec 31, 2023 |
FY 2022 Dec 31, 2022 |
FY 2021 Dec 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $1.0B | $940.2M | $747.7M | $801.2M | $702.8M |
| Operating income | -$187.3M | -$99.1M | -$233.2M | -$92.8M | $22.7M |
| Net income | -$204.7M | -$96.0M | -$222.6M | -$94.6M | $15.6M |
| Diluted EPS | -$3.04 | -$1.47 | -$3.43 | -$1.47 | $0.24 |
| Operating cash flow | -$9.7M | $24.2M | -$31.8M | $50.5M | $111.4M |
| Free cash flow | -$29.7M | $5.0M | -$58.6M | $16.4M | $97.2M |
| Total assets | $881.1M | $967.7M | $952.7M | $1.1B | $905.1M |
| Total liabilities | $725.9M | $704.6M | $639.0M | $612.8M | $472.0M |
| Stockholders' equity | $155.2M | $263.1M | $313.6M | $439.9M | $433.1M |
| Cash and investments | $292.7M | $438.3M | $467.9M | $616.9M | $623.8M |
| Total debt | $444.5M | $473.6M | $130.6M | $136.6M | $33.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 10-Q | Quarterly report | Aug 6, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 6, 2026 | Aug 6, 2026 |
| 8-K |
Current report
Change to shareholder rights, Officer or director change, Shareholder vote results
|
May 21, 2026 | May 20, 2026 |
| 8-K |
Current report
Officer or director change
|
May 15, 2026 | May 11, 2026 |
| 10-Q | Quarterly report | May 7, 2026 | Mar 31, 2026 |
| 8-K |
Current report
Results of operations
|
May 7, 2026 | May 7, 2026 |
All 1004 Tandem Diabetes Care, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.